Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
José Aguareles, Juan Paraíso‐Luna, Belén Palomares, et al.
Translational Neurodegeneration (2019) Vol. 8, Iss. 1
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
Ayat Zagzoog, Kawthar A. Mohamed, Hye Ji J. Kim, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 146
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
Barbara Stella, Francesca Baratta, Carlo Della Pepa, et al.
Drugs (2021) Vol. 81, Iss. 13, pp. 1513-1557
Open Access | Times Cited: 104
A systematic review of minor phytocannabinoids with promising neuroprotective potential
Nicole L. Stone, Alexandra J. Murphy, Timothy J. England, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 19, pp. 4330-4352
Open Access | Times Cited: 86
Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases
Orkid Coskuner‐Weber, Ozan Mirzanli, Vladimir N. Uversky
Biophysical Reviews (2022) Vol. 14, Iss. 3, pp. 679-707
Open Access | Times Cited: 46
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
Fabrizio Calapai, Luigi Cardia, Emanuela Esposito, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-14
Open Access | Times Cited: 43
An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom
Jonathan Paul Liebling, Nicholas James Clarkson, Blair William Gibbs, et al.
Cannabis and Cannabinoid Research (2020) Vol. 7, Iss. 2, pp. 207-213
Open Access | Times Cited: 58
Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
Leontina Elena Filipiuc, Daniela Carmen Ababei, Teodora Alexa‐Stratulat, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1823-1823
Open Access | Times Cited: 56
The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders
Anna Stasiłowicz-Krzemień, Wiktoria Nogalska, Zofia Maszewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5749-5749
Open Access | Times Cited: 8
Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health
Vidyasagar Naik Bukke, Archana Moola, Rosanna Villani, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 965-965
Open Access | Times Cited: 40
Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System
Ana Lago-Fernandez, Sara Zarzo-Arias, Nadine Jagerovic, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1001-1001
Open Access | Times Cited: 39
Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition
Noemí Cárdenas‐Rodríguez, Iván Ignacio‐Mejía, José Correa‐Basurto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3805-3805
Open Access | Times Cited: 5
Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds
Brittney R. Lins, Chidozie C. Anyaegbu, Sarah C. Hellewell, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 12
Novel approaches and current challenges with targeting the endocannabinoid system
Paula Morales, Nadine Jagerovic
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 8, pp. 917-930
Open Access | Times Cited: 30
Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances
Aaron Mark Farrelly, Styliani Vlachou, Konstantinos Grintzalis
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 8, pp. 3993-3993
Open Access | Times Cited: 27
Multilayered neuroprotection by cannabinoids in neurodegenerative diseases
Ahmed Hasbi, Susan R. George
Exploration of Neuroprotective Therapy (2025) Vol. 5
Open Access
Multilayered neuroprotection by cannabinoids in neurodegenerative diseases
Ahmed Hasbi, Susan R. George
Exploration of Neuroprotective Therapy (2025) Vol. 5
Open Access
Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Graziella dos Reis Rosa Franco, Scott D. Smid, Cláudio Viegas
Current Neuropharmacology (2020) Vol. 19, Iss. 4, pp. 449-464
Open Access | Times Cited: 27
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Sonia Burgaz, Concepción García, María Gómez‐Cañas, et al.
Molecular and Cellular Neuroscience (2020) Vol. 110, pp. 103583-103583
Closed Access | Times Cited: 24
Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
Andrea Valeri, Emanuela Mazzon
Molecules (2021) Vol. 26, Iss. 20, pp. 6313-6313
Open Access | Times Cited: 16
Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents
Dylan T. Marsh, Scott D. Smid
Australian Journal of Chemistry (2020) Vol. 74, Iss. 6, pp. 388-404
Closed Access | Times Cited: 16
Will Cannabigerol Trigger Neuroregeneration after a Spinal Cord Injury? An In Vitro Answer from NSC-34 Scratch-Injured Cells Transcriptome
Andrea Valeri, Luigi Chiricosta, Agnese Gugliandolo, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 117-117
Open Access | Times Cited: 9
Cannabinoquinones: Synthesis and Biological Profile
Diego Caprioglio, Daiana Mattoteia, Orazio Taglialatela‐Scafati, et al.
Biomolecules (2021) Vol. 11, Iss. 7, pp. 991-991
Open Access | Times Cited: 7
Early Consumption of Cannabinoids: From Adult Neurogenesis to Behavior
Citlalli Netzahualcoyotzi, Luis Miguel Rodríguez–Serrano, María Elena Chávez–Hernández, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7450-7450
Open Access | Times Cited: 6
The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
Santiago Rodríguez-Carreiro, Elisa Navarro, Eduardo Muñóz, et al.
Brain Sciences (2023) Vol. 13, Iss. 9, pp. 1272-1272
Open Access | Times Cited: 2
Interplay Between Endocannabinoid System and Neurodegeneration: Focus on Polypharmacology
Francesca Seghetti, Silvia Gobbi, Federica Belluti, et al.
Current Medicinal Chemistry (2021) Vol. 29, Iss. 28, pp. 4796-4830
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top